Clinical Research on "Tongdu Zhiyu" Acupuncture Method for Post-Stroke Depression Based on Neuroimaging Technology.

注册号:

Registration number:

ITMCTR2024000410

最近更新日期:

Date of Last Refreshed on:

2024-09-10

注册时间:

Date of Registration:

2024-09-10

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

基于神经影像技术探究“通督治郁”针法治疗脑卒中后抑郁的临床研究

Public title:

Clinical Research on "Tongdu Zhiyu" Acupuncture Method for Post-Stroke Depression Based on Neuroimaging Technology.

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于神经影像技术探究“通督治郁”针法治疗脑卒中后抑郁的临床研究

Scientific title:

Clinical Research on "Tongdu Zhiyu" Acupuncture Method for Post-Stroke Depression Based on Neuroimaging Technology.

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王震

研究负责人:

王震

Applicant:

Wang Zhen

Study leader:

Wang Zhen

申请注册联系人电话:

Applicant telephone:

13856069597

研究负责人电话:

Study leader's telephone:

13856069597

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1574985610@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1574985610@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

安徽省合肥市庐阳区寿春路300号

研究负责人通讯地址:

安徽省合肥市庐阳区寿春路300号

Applicant address:

No. 300 Shouchun Road Luyang District Hefei City Anhui Province China.

Study leader's address:

No. 300, Shouchun Road, Luyang District, Hefei City, Anhui Province, China.

申请注册联系人邮政编码:

Applicant postcode:

230000

研究负责人邮政编码:

Study leader's postcode:

230000

申请人所在单位:

安徽中医药大学第二附属医院脑病六科

Applicant's institution:

"The Sixth Department of Brain Diseases The Second Affiliated Hospital of Anhui University of Chinese Medicine"

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2023-zj-39

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

安徽中医药大学第二附属医院伦理委员会

Name of the ethic committee:

The Ethics Committee of The Second Affiliated Hospital of Anhui University of Chinese Medicine.

伦理委员会批准日期:

Date of approved by ethic committee:

2024/1/19 0:00:00

伦理委员会联系人:

束樱子

Contact Name of the ethic committee:

Shu Ying Zi

伦理委员会联系地址:

安徽省合肥市庐阳区寿春路300号安徽省针灸医院

Contact Address of the ethic committee:

No. 300 Shouchun Road Luyang District Hefei City Anhui Province China.

伦理委员会联系人电话:

Contact phone of the ethic committee:

0551-62668814

伦理委员会联系人邮箱:

Contact email of the ethic committee:

346506963@qq.com

研究实施负责(组长)单位:

安徽中医药大学第二附属医院

Primary sponsor:

"The Sixth Department of Brain Diseases The Second Affiliated Hospital of Anhui University of Chinese Medicine"

研究实施负责(组长)单位地址:

安徽省合肥市庐阳区寿春路300号

Primary sponsor's address:

No. 300 Shouchun Road Luyang District Hefei City Anhui Province China.

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

安徽

市(区县):

合肥

Country:

China

Province:

Anhui Province

City:

Hefei City

单位(医院):

安徽中医药大学第二附属医院脑病六科

具体地址:

安徽省合肥市庐阳区寿春路300号安徽省针灸医院

Institution
hospital:

"The Sixth Department of Brain Diseases The Second Affiliated Hospital of Anhui University of Chinese Medicine"

Address:

No. 300 Shouchun Road Luyang District Hefei City Anhui Province China.

经费或物资来源:

安徽中医药大学第二附属医院脑病六科

Source(s) of funding:

"The Sixth Department of Brain Diseases The Second Affiliated Hospital of Anhui University of Chinese Medicine"

研究疾病:

卒中后抑郁

研究疾病代码:

Target disease:

Post-stroke depression.

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

治疗新技术临床试验

New Treatment Measure Clinical Study

研究目的:

从脑区磁共振弥散张量成像(DTI)和磁共振波谱成像(MRS)层面深入研究“通督治郁”针法治疗卒中后抑郁的的调控干预作用,观察“通督治郁”针法治疗对相关数据的有效性,证实“通督治郁”针法治疗脑卒中后抑郁的有效性,明确针灸在脑卒中后抑郁治疗中不同疗效和获益环节,并获得高级别循证医学证据,形成规范化诊疗方案并推广应用。

Objectives of Study:

To conduct an in-depth study on the regulatory intervention effects of "Tongdu Zhiyu" acupuncture in treating post-stroke depression from the perspectives of diffusion tensor imaging (DTI) and magnetic resonance spectroscopy (MRS) observe the effectiveness of the relevant data confirm the effectiveness of "Tongdu Zhiyu" acupuncture in treating post-stroke depression clarify the different therapeutic effects and beneficial links of acupuncture in the treatment of post-stroke depression obtain high-level evidence-based medical evidence and formulate a standardized diagnosis and treatment plan for promotion and application.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

病例选择标准 (1)脑卒中诊断标准:参照《中国各类主要脑血管病诊断要点》[1],经颅脑CT或MRI检查确诊。 (2) PSD诊断标准:1)西医诊断标准:参照《中国中风后抑郁症临床实践指南》[2]诊断标准。临床表现为情绪低落,悲观厌世, 精神运动迟缓、兴趣减弱、烦躁易疲劳以及思维迟缓等。2)中医辨病辨证标准:参照《中医内科学》第五版和《中医病症诊断疗效标准》 确立如下诊断标准:①发生在中风之后,因情志不舒、气机郁滞致病;②忧郁不畅、精神不振、胸闷胁胀,或脘痞、嗳气频作,善太息,女子月经不调;③有郁闷、多虑、悲哀、忧愁等情志所伤史;④经各系统检查和实验室检查排除器质性病变。 (3)病例纳入标准: ①符合上述诊断标准;②基础疾病控制平稳,符合症状标准和严重标准至少持续2周,卒中病程在1年以内;③患者的汉密尔顿抑郁量表的24 项评分≥9分;④既往没有抑郁障碍及服用抗抑郁药物;⑤患者及家属对本研究知情同意并且签署知情同意书;⑥男女均可

Inclusion criteria

Inclusion criteria for case selection: 1. Diagnostic criteria for stroke: Diagnosed by cranial CT or MRI in accordance with the "Diagnostic Guidelines for Various Types of Cerebrovascular Diseases in China"[1]. 2. Diagnostic criteria for post-stroke depression (PSD): a. Western medicine diagnostic criteria: Refer to the "Chinese Clinical Practice Guidelines for Post-Stroke Depression"[2] for diagnostic criteria. Clinical manifestations include symptoms such as low mood pessimism psychomotor retardation reduced interest irritability fatigue and slow thinking. b. Traditional Chinese medicine (TCM) diagnostic and syndrome differentiation criteria: Based on the 5th edition of "TCM Internal Science" and "Diagnostic and Therapeutic Criteria for TCM Diseases and Symptoms" the following diagnostic criteria are established: i. Occurs after stroke caused by emotional discomfort and stagnation of Qi. ii. Symptoms such as melancholy low spirits chest and rib-side distension or abdominal (a type of discomfort in TCM) frequent belching frequent sighing and menstrual irregularities in women. iii. A history of emotional stress with symptoms such as depression overthinking sadness and sorrow. iv. Exclusion of organic diseases through systemic examinations and laboratory tests. 3. Case inclusion criteria: a. Meet the above diagnostic criteria. b. Underlying diseases are well-controlled with symptoms and severity criteria lasting for at least 2 weeks and the course of stroke within 1 year. c. The patient's 24-item Hamilton Depression Scale score is ≥9. d. No history of depressive disorder or use of antidepressant medication. e. The patient and family provide informed consent for this study and have signed the informed consent form. f.Both men and women are applicable.

排除标准:

①患者既往有痴呆或影响认知功能的神经系统疾病; ②患者有视觉障碍或交流困难; ③患者有严重的脏器出现衰竭或者功能障碍; ④患者身体上有严重的疾病,如恶性肿瘤等可能严重影响到研究的结果; ⑤患者有精神系统疾病,无法提供病史和配合研究; ⑥患者有对研究中所使用药物有过敏史。

Exclusion criteria:

Exclusion criteria for patients: 1. Patients with a history of dementia or neurological diseases that affect cognitive function. 2. Patients with visual impairments or communication difficulties. 3. Patients with severe organ failure or dysfunction. 4. Patients with severe physical illnesses such as malignant tumors that may significantly impact the study results. 5. Patients with mental disorders that prevent them from providing medical history and cooperating with the study. 6. Patients with a history of allergy to the medications used in the study.

研究实施时间:

Study execute time:

From 2024-01-20

To      2025-12-20

征募观察对象时间:

Recruiting time:

From 2024-01-20

To      2024-12-20

干预措施:

Interventions:

组别:

空白组

样本量:

20

Group:

Blank group

Sample size:

干预措施:

干预措施代码:

Intervention:

no

Intervention code:

组别:

对照组

样本量:

20

Group:

Control group

Sample size:

干预措施:

普通针刺

干预措施代码:

Intervention:

General acupuncture

Intervention code:

组别:

观察组

样本量:

20

Group:

Observation group.

Sample size:

干预措施:

对照组穴位+“通督治郁”针刺

干预措施代码:

Intervention:

Control group acupoints + "Tongdu Zhiyu" acupuncture

Intervention code:

样本总量 Total sample size : 60

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

安徽

市(区县):

合肥

Country:

China

Province:

Anhui Province

City:

Hefei City

单位(医院):

安徽中医药大学第二附属医院脑病六科

单位级别:

三甲

Institution/hospital:

"The Sixth Department of Brain Diseases The Second Affiliated Hospital of Anhui University of Chinese Medicine"

Level of the institution:

Tertiary (level 3) Grade A (top grade) hospital.

测量指标:

Outcomes:

指标中文名:

血清ELISA

指标类型:

次要指标

Outcome:

Serum ELISA

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Barthel指数

指标类型:

次要指标

Outcome:

Barthel Index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

FA值

指标类型:

次要指标

Outcome:

Fractional Anisotropy

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

美国国立卫生院研究院卒中神经功能缺损评分量表(NHISS)评分

指标类型:

次要指标

Outcome:

National Institutes of Health Stroke Scale (NIHSS) score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

抗抑郁药副反应量表(SERS)

指标类型:

次要指标

Outcome:

Rating Scale for Side Effects

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

24项汉密尔顿抑郁量表(HAMD)评分

指标类型:

主要指标

Outcome:

24-item Hamilton Depression Rating Scale (HAMD) score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

磁共振波谱成像(MRS)测定

指标类型:

主要指标

Outcome:

Magnetic Resonance Spectroscopy (MRS) measurement

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

BDNF的DNA甲基化

指标类型:

次要指标

Outcome:

BDNF DNA methylation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

弥散张量成像指标(DTI)测定

指标类型:

主要指标

Outcome:

Diffusion Tensor Imaging (DTI) metrics measurement

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 20
Min age years
最大 70
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

将患者分为观察组、对照组,每组20例,运用SPSS23.0软件按1:1比例随机序列法产生随机号和组别信息,分装于1~40 号密封信封中,由专职护士保管并按照患者首次治疗的顺序抽取信封,并根据信封内的方案分组。患者、护士、医师及数据统计者不知分组方案直至揭盲。

Randomization Procedure (please state who generates the random number sequence and by what method):

The patients were divided into an observation group and a control group, with 20 cases in each group. The SPSS 23.0 software was used to generate random numbers and group information in a 1:1 ratio according to the random sequence method. These were then placed in sealed envelopes numbered from 1 to 40. A dedicated nurse kept these envelopes and抽取 them according to the order of the patients' first treatment, grouping the patients based on the scheme inside the envelope. Neither the patients, nurses, physicians, nor the data statisticians knew the grouping scheme until the blinding was revealed.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

http://www.medresman.org.cn/uc/index.aspx

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

http://www.medresman.org.cn/uc/index.aspx

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above